3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Smoldering Multiple Myeloma
2
Prostatic Neoplasms
2
Monoclonal Gammopathy of Undetermined Significance
2
Uterine Cervical Neoplasms
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Psychological Well-Being
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Neoplasms
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Motor Activity
1
Lung Neoplasms
1
Locally Advanced Cervical Cancer
1
Esophageal Neoplasms
1
Castration Sensitive Prostate Cancer
1
Interventions
pembrolizumab
16
Radiotherapy
15
Drug Therapy
14
Paclitaxel
13
Cisplatin
12
Carboplatin
10
Immunotherapy
9
Esophagectomy
9
Radiation
8
Fluorouracil
8
Surgical Procedures, Operative
7
Capecitabine
7
Blood Specimen Collection
7
Oxaliplatin
6
Nivolumab
6
Immune Checkpoint Inhibitors
6
Chemoradiotherapy
6
nimotuzumab
5
Trastuzumab
5
130-nm albumin-bound paclitaxel
5
sintilimab
4
camrelizumab
4
Leucovorin
4
trastuzumab deruxtecan
3
tislelizumab
3
patritumab deruxtecan
3
Surveys and Questionnaires
3
Endoscopy
3
Bevacizumab
3
toripalimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Esophageal Neoplasms
×
Curcumin
×
Clear all
NCT04871412
2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3
Recruiting
20 enrolled